신덕약품

비상장계속사업자

Shinduk

김정도

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

신덕약품

Business Reg. No. 2098110797 · CEO 김정도

I.Investment Overview

Target신덕약품 (2098110797)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명신덕약품
영문명Shinduk
대표자김정도
사업자등록번호2098110797
법인등록번호1101110794944
설립일1991.08.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1,532.320211,762.920221,887.920231,977.720242,149.52025
영업이익100M KRW31.8202131.5202230.6202327.9202428.12025
순이익100M KRW25.5202125.5202225.4202325202426.12025
Item20252024202320222021
자산총계499.1억원481.2억원447.6억원425.9억원389.5억원
부채총계163.7억원171.9억원163.3억원167억원156.1억원
자본총계335.4억원309.3억원284.3억원258.9억원233.4억원
매출액2,149.5억원1,977.7억원1,887.9억원1,762.9억원1,532.3억원
영업이익28.1억원27.9억원30.6억원31.5억원31.8억원
순이익26.1억원25억원25.4억원25.5억원25.5억원

VI.Financial Ratios

FY2025 basis

1.31%

영업이익률

1.22%

순이익률

5.23%

ROA

7.79%

ROE

48.8%

부채비율

67.21%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

신덕약품 투심보고서 | Alpha Lenz